市場調查報告書
商品編碼
1470805
感染疾病診斷市場:按產品、技術、測試類型、樣本、應用和最終用戶分類 - 全球預測 2024-2030Infectious Disease Diagnostic Market by Product (Instruments, Reagents, Software & Services), Technology (Biochemical Technology, Conventional Technology, Molecular Technology), Testing Type, Sample, Application, End User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年感染疾病診斷市場規模為247.6億美元,預計2024年將達264.4億美元,2030年將達405.3億美元,複合年成長率為7.29%。
感染疾病診斷產品旨在檢測和識別引起人類感染疾病的病原體。這些診斷透過準確、及時地識別傳染源以及及時、適當的臨床管理,在醫療保健中發揮重要作用。診斷感染疾病的診斷方法包括培養方法、分子診斷方法、血清學測試、基於抗原的測試和次世代定序方法,它有助於實施感染控制措施,以防止病原體在醫療機構內傳播。近年來,由於感染疾病的爆發,迫切需要高可靠性的診斷試劑。此外,全球醫療保健支出的增加和實驗室基礎設施的改善也促進了感染疾病診斷解決方案的普及。此外,政府對創新診斷解決方案的措施和監管部門的核准正在擴大新感染疾病解決方案的可用性。然而,與先進診斷技術相關的高成本可能會限制其在成本敏感地區的採用。新興市場缺乏熟練的專業人員來操作先進的診斷設備可能會限制我們產品的普及。然而,隨著先進技術的整合增強了複雜診斷測試的資料分析和解釋,診斷測試的產出正在改善。此外,快速 PCR 系統和次世代定序等診斷技術的不斷進步,透過提供更快、更準確的結果,推動了對感染疾病診斷產品的需求。
主要市場統計 | |
---|---|
基準年[2023] | 247.6億美元 |
預測年份 [2024] | 264.4億美元 |
預測年份 [2030] | 405.3億美元 |
複合年成長率(%) | 7.29% |
產品感染疾病診斷分析儀器應用的演變
分析設備包括用於診斷感染疾病的各種分析設備,從基本的檢測設備到先進的診斷設備,如PCR系統、免疫測量、微生物培養和分子診斷平台。測試設備對於需要實驗室測試以獲得快速可靠結果的實驗室、醫院和診所至關重要。試劑構成用於檢測臨床樣本中病原體的生化物質或混合物。試劑包括用於PCR測試的引子、探針、酵素、緩衝液、用於免疫測量的抗體以及用於細菌生長的各種培養基。不同的疾病需要特定的試劑來進行準確的檢測,並且偏好根據感興趣的病原體而變化。軟體和服務包括資料分析軟體、整合各種診斷平台的互通性解決方案、實驗室管理、技術支援和諮詢服務。軟體和服務對於實際解釋診斷測試並將診斷資料與患者記錄整合至關重要。提供者通常更喜歡易於使用、強大的資料分析功能以及與現有系統相容的軟體。
測試類型:新興的便利和緊急應用現場護理 (PoC) 測試
實驗室測試分析樣本以檢測感染疾病,並在受控環境中使用特殊設備進行。實驗室測試通常被認為是黃金標準,因為其準確性高且能夠提供全面的結果。實驗室檢測的偏好源於需要準確和詳細的診斷來指南有效的治療計劃。準確度高、分析全面的實驗室檢測是確診的更可靠選擇,適用於時間限制較少的複雜病例。另一方面,照護端 (PoC) 測試是在患者照護端或附近進行的診斷測試。 PoC 測試的主要優點是其方便且快速的結果,這對於臨床決策至關重要。 PoC 測試可以使用可攜式設備或快速檢測套組(例如橫向流動測定)進行,並且在資源有限的環境或需要即時結果的情況下需要。
應用擴大使用疾病診斷套件來診斷病毒感染
細菌感染疾病的診斷涉及識別引起結核病、肺炎和尿道感染等疾病的病原菌。醫療機構對細菌診斷的需求量很大,快速診斷工具對於及時治療至關重要,並且可以減少感染疾病的傳播。心血管感染疾病的診斷包括檢測致病菌的分子和血清學檢查。中樞神經系統 (CNS)感染疾病(包括腦膜炎和腦炎)可能很嚴重,需要及時、準確的診斷。真菌感染疾病的診斷對於免疫力缺乏的患者至關重要,因為念珠菌症和麴菌症等感染疾病會危及生命。多種診斷測試用於診斷真菌疾病,從傳統培養方法到先進的分子診斷平台。 HIV、HPV、披衣菌感染和淋病等性行為感染傳染病 (STD) 的診斷對於公共衛生至關重要。這些診斷劑非常需要,因為它們影響許多人,並對生殖健康產生嚴重影響。病毒診斷涵蓋流感、肝炎和新出現的病原體等多種疾病。
最終用戶:感染疾病診斷產品在醫院的普及
診斷實驗室是進行傳染病檢查的專業設施。需要高通量系統、擴充性和全面的測試選單來滿足各種診斷需求。診斷實驗室優先考慮自動化平台、與實驗室資訊系統的整合以及處理大量檢體的經濟有效的測試。醫院是治療感染疾病患者的關鍵點。醫院需要快速、準確且易於整合到內部患者照護工作流程中的診斷工具。醫院正在尋求診斷解決方案,例如就地檢驗設備,以最大限度地縮短診斷時間,以改善患者管理和隔離通訊協定。研究機構專注於感染疾病的研究,以了解其本質並開發新的診斷技術。研究機構需要複雜而靈敏的設備來在分子層面上檢測和研究病原體。研究機構對最尖端科技、檢測能力的多樣性以及針對不同病原體的多種檢測方法感興趣。
區域洞察
由於感染疾病的傳播、診斷技術的進步以及早期疾病檢測意識的提高,美洲的感染疾病診斷市場正在經歷快速成長。先進技術的採用、成熟的醫療基礎設施以及眾多供應商的存在正在為美洲的感染疾病診斷市場做出貢獻。歐盟 (EU) 法規和複雜的醫療保健系統對歐洲市場產生重大影響。歐盟國家正在大力投資研究和創新,這與客戶在疾病預防和控制方面採取的積極行動產生共鳴,加速先進診斷技術開發的舉措就是例證。中東市場以高醫療保健支出和引進高科技診斷設備為導向,特別是在波灣合作理事會(GCC)國家。在非洲,對容易取得且負擔得起的診斷試劑的需求不斷成長,以對抗愛滋病毒/愛滋病、結核病和瘧疾等流行感染疾病,對感染疾病診斷產品的需求也不斷成長。由於人口眾多、醫療費用不斷上漲,亞太地區的感染疾病診斷市場正迅速擴大。政府對醫療改革的關注和國內公司的崛起正在促進感染疾病診斷的成長。
FPNV定位矩陣
FPNV 定位矩陣對於評估感染疾病診斷市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對感染疾病診斷市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4. 競爭評估和情報:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1.感染疾病診斷市場的市場規模和預測是多少?
2.在感染疾病診斷市場的預測期間內,有哪些產品、細分市場、應用和領域需要考慮投資?
3.感染疾病診斷市場的技術趨勢和法規結構是什麼?
4.感染疾病診斷市場主要廠商的市場佔有率為何?
5.進入感染疾病診斷市場的合適型態和策略手段是什麼?
[183 Pages Report] The Infectious Disease Diagnostic Market size was estimated at USD 24.76 billion in 2023 and expected to reach USD 26.44 billion in 2024, at a CAGR 7.29% to reach USD 40.53 billion by 2030.
Infectious disease diagnostics products are designed to detect and identify pathogens that cause human infections. These diagnostics play a critical role in healthcare by facilitating the accurate and timely recognition of infectious agents, thus ensuring prompt and appropriate clinical management. The modalities for infectious disease diagnostics include culture techniques, molecular diagnostics, serology, antigen-based tests, and next-generation sequencing for guiding treatment decisions, monitoring disease outbreaks, and implementing infection control measures to prevent the spread of pathogens within communities and healthcare settings. In recent years, outbreaks of infectious diseases have resulted in an urgent need for reliable diagnostics. In addition, growth in healthcare spending and improvements in laboratory infrastructure globally contribute to the penetration of infectious disease diagnostic solutions. Moreover, government initiatives and regulatory approvals for innovative diagnostic solutions have expanded the availability of novel infectious disease diagnostic solutions. However, high costs associated with advanced diagnostic technologies could limit adoption in cost-sensitive regions. The lack of skilled professionals in emerging markets to operate sophisticated diagnostic equipment may restrict product penetration. Nevertheless, the integration of advanced technologies for enhanced data analysis and interpretation of complex diagnostic tests has enhanced the outputs of diagnostic tests. In addition, continuous development in diagnostic technologies, including rapid PCR systems and next-generation sequencing, drives the demand for infectious disease diagnostics products by offering quicker and more accurate results.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 24.76 billion |
Estimated Year [2024] | USD 26.44 billion |
Forecast Year [2030] | USD 40.53 billion |
CAGR (%) | 7.29% |
Product: Advancing applications of analytical instruments for infectious disease diagnostics
The instruments include various analytical devices for diagnosing infectious diseases, ranging from essential laboratory equipment to sophisticated diagnostic machines such as PCR systems, immunoassays, microbiology cultures, and molecular diagnostics platforms. Instruments are crucial for laboratories, hospitals, and clinics requiring in-house testing for fast and reliable results. Reagents constitute the biochemical substances and mixtures used to detect pathogens in clinical samples. Reagents include primers, probes, enzymes, and buffers for PCR tests, antibodies for immunoassays, and various culture media for bacterial growth. Different diseases require specific reagents for accurate detection; hence, the preference varies based on the pathogen of interest. Software & services include data analysis software, interoperability solutions for integrating various diagnostic platforms, and services such as lab management, technical support, and consultancy. Software and services are critical for practically interpreting diagnostic tests and integrating diagnostics data with patient records. Providers usually prefer software that offers ease of use, robust data analysis capabilities, and compatibility with existing systems.
Testing Type: Emerging adoption of Point-of-Care (PoC) testing for convenience and emergency applications
Laboratory testing analyzes samples to detect infectious diseases, which is done in a controlled environment with specialized equipment. Laboratory testing is often considered the gold standard due to its high accuracy and ability to provide comprehensive results. The preference for laboratory testing arises from the need for precise and detailed diagnostics that can guide effective treatment plans. With its enhanced precision and capacity for comprehensive analysis, laboratory testing is the more reliable option for definitive diagnostics and is suited for complex cases with less time sensitivity. On the other hand, Point-of-Care (PoC) testing is diagnostic testing performed at or near the site of patient care. The critical advantage of PoC testing is its convenience and the rapidity with which results can be obtained, which is essential in clinical decision-making. PoC testing can be performed with portable instruments or simple test kits, such as lateral flow assays, and is necessary in resource-limited settings or situations where immediate results are required.
Application: Increasing use of disease diagnosis kits to diagnose viral infections
Diagnostics for bacterial infections involve the identification of pathogenic bacteria that can cause disorders such as tuberculosis, pneumonia, and urinary tract infections. Need-based preference for bacterial diagnostics is high in healthcare settings where rapid diagnostic tools are essential for timely treatment, thus reducing the spread of infections. Diagnostics for cardiovascular infections involve molecular tests and serology testing to detect pathogenic organisms. Central Nervous System (CNS) infections can include meningitis and encephalitis and require rapid and accurate diagnostics due to their potential severity. Fungal infection diagnostics are essential for immunocompromised patients, where infections including candidiasis and aspergillosis can be life-threatening. Diagnostic tests range from traditional culture methods to advanced molecular diagnostic platforms to diagnose fungal disorders. Diagnostics for sexually transmitted diseases (STDs) such as HIV, HPV, chlamydia, and gonorrhea are crucial for public health. These diagnostics have a high need-based preference because they affect a large demographic and can have serious reproductive health consequences. Viral diagnostics cover various diseases, including influenza, hepatitis, and emerging pathogens.
End-User: Penetration of infectious disease diagnosis products in hospitals
Diagnostic laboratories are specialized facilities where infectious disease tests are conducted. They require high throughput systems, scalability, and comprehensive test menus to cater to varied diagnostic needs. Diagnostic laboratories prioritize automated platforms, integration with laboratory information systems, and cost-effective testing to handle high volumes of samples. Hospitals form a critical point of care for patients suffering from infectious diseases. Hospitals require diagnostic tools that are fast, accurate, and can be easily integrated into the patient care workflow within their facilities. Hospitals seek diagnostic solutions that minimize time to diagnosis to improve patient management and isolation protocols, such as point-of-care testing devices. Research institutes focus on studying infectious diseases to understand their nature and develop new diagnostic technologies. Research institutes require sophisticated and susceptible equipment to detect and study pathogens at a molecular level. Research institutes are interested in cutting-edge technology, versatility in testing capabilities, and access to various assays for different pathogens.
Regional Insights
The infectious disease diagnostic market in the Americas is observing rapid growth due to the increasing prevalence of infectious diseases, advanced diagnostic technologies, and growing awareness of early disease detection. The adoption of advanced technologies, well-established healthcare infrastructure, and the presence of the majority of vendors contribute to the infectious disease diagnostic market in the Americas. European Union's (EU) regulations and a sophisticated healthcare system largely influence Europe's market. EU countries invest heavily in research and innovation, exemplified by initiatives to foster the development of advanced diagnostics and resonate with proactive customer behavior toward disease prevention and management. The Middle East market is directed by significant healthcare spending and the adoption of high-tech diagnostic equipment, particularly in Gulf Cooperation Council (GCC) countries. The need for accessible and affordable diagnostics to combat prevalent infectious diseases such as HIV/AIDS, tuberculosis, and malaria has improved the need for infectious disease diagnosis products in Africa. The infectious disease diagnostic market in the Asia-Pacific is expanding rapidly due to its large population and increased healthcare expenditure. The government's focus on healthcare reform and the rise of domestic companies contribute to the growth of infectious disease diagnostics.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Infectious Disease Diagnostic Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Infectious Disease Diagnostic Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Infectious Disease Diagnostic Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaptive Biotechnologies Corporation, Agilent Technologies, Inc., Becton, Dickinson and Company, Bio-Techne Corporation, bioMerieux SA, Cardinal Health Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., GE Healthcare, Grifols, S.A., Hologic Inc., Illumina, Inc., Johnson & Johnson Services, Inc., Konica Minolta, Inc., Labsystems Diagnostics Oy, Merck KGaA, Olympus Corporation, Perkin Elmer, Inc., Pfizer Inc., Qiagen N.V., Quest Diagnostics, Siemens Healthineers AG, Sysmex Corporation, and Thermo Fisher Scientific, Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Infectious Disease Diagnostic Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Infectious Disease Diagnostic Market?
3. What are the technology trends and regulatory frameworks in the Infectious Disease Diagnostic Market?
4. What is the market share of the leading vendors in the Infectious Disease Diagnostic Market?
5. Which modes and strategic moves are suitable for entering the Infectious Disease Diagnostic Market?